Advances in primary sclerosing cholangitis

Jennifer L. Horsley-Silva, Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated with inflammatory bowel disease. Although the cause of the disease is still debated, a genetic association and link to immune-mediated disease triggered by environmental factors are thought to contribute. The disease can present as isolated imaging abnormalities, biochemical changes, cholangiocarcinoma, or end-stage complications such as cirrhosis. Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea. Differentiation of primary sclerosing cholangitis can be challenging because other chronic cholangiopathies can present similarly; however, the distinction is necessary to optimise disease surveillance. Management involves assessment for comorbid inflammatory bowel disease and exclusion of other associated cholangiopathic disorders. Patients with primary sclerosing cholangitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepatobiliary and colorectal cancers is present in those with inflammatory bowel disease. Although much research involves locating an active therapy that can alter the disease course, the only available treatment is liver transplantation, and risk for disease recurrence remains. Use of ursodeoxycholic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease course. In this Review, we summarise aetiological theories, provide an update on hepatobiliary malignancies that require surveillance, and discuss exciting areas of investigation for potential treatment.

Original languageEnglish (US)
Pages (from-to)68-77
Number of pages10
JournalThe Lancet Gastroenterology and Hepatology
Volume1
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Sclerosing Cholangitis
Inflammatory Bowel Diseases
Steatorrhea
Ursodeoxycholic Acid
Cholangiocarcinoma
Immune System Diseases
Pruritus
Jaundice
Bilirubin
Liver Cirrhosis
Liver Transplantation
Fatigue
Alkaline Phosphatase
Colorectal Neoplasms
Fibrosis
Therapeutics
Recurrence
Research
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Advances in primary sclerosing cholangitis. / Horsley-Silva, Jennifer L.; Carey, Elizabeth J.; Lindor, Keith.

In: The Lancet Gastroenterology and Hepatology, Vol. 1, No. 1, 2016, p. 68-77.

Research output: Contribution to journalReview article

Horsley-Silva, Jennifer L. ; Carey, Elizabeth J. ; Lindor, Keith. / Advances in primary sclerosing cholangitis. In: The Lancet Gastroenterology and Hepatology. 2016 ; Vol. 1, No. 1. pp. 68-77.
@article{554f2923706d4ceab8db98563c6ba820,
title = "Advances in primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated with inflammatory bowel disease. Although the cause of the disease is still debated, a genetic association and link to immune-mediated disease triggered by environmental factors are thought to contribute. The disease can present as isolated imaging abnormalities, biochemical changes, cholangiocarcinoma, or end-stage complications such as cirrhosis. Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea. Differentiation of primary sclerosing cholangitis can be challenging because other chronic cholangiopathies can present similarly; however, the distinction is necessary to optimise disease surveillance. Management involves assessment for comorbid inflammatory bowel disease and exclusion of other associated cholangiopathic disorders. Patients with primary sclerosing cholangitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepatobiliary and colorectal cancers is present in those with inflammatory bowel disease. Although much research involves locating an active therapy that can alter the disease course, the only available treatment is liver transplantation, and risk for disease recurrence remains. Use of ursodeoxycholic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease course. In this Review, we summarise aetiological theories, provide an update on hepatobiliary malignancies that require surveillance, and discuss exciting areas of investigation for potential treatment.",
author = "Horsley-Silva, {Jennifer L.} and Carey, {Elizabeth J.} and Keith Lindor",
year = "2016",
doi = "10.1016/S2468-1253(16)30010-3",
language = "English (US)",
volume = "1",
pages = "68--77",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Advances in primary sclerosing cholangitis

AU - Horsley-Silva, Jennifer L.

AU - Carey, Elizabeth J.

AU - Lindor, Keith

PY - 2016

Y1 - 2016

N2 - Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated with inflammatory bowel disease. Although the cause of the disease is still debated, a genetic association and link to immune-mediated disease triggered by environmental factors are thought to contribute. The disease can present as isolated imaging abnormalities, biochemical changes, cholangiocarcinoma, or end-stage complications such as cirrhosis. Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea. Differentiation of primary sclerosing cholangitis can be challenging because other chronic cholangiopathies can present similarly; however, the distinction is necessary to optimise disease surveillance. Management involves assessment for comorbid inflammatory bowel disease and exclusion of other associated cholangiopathic disorders. Patients with primary sclerosing cholangitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepatobiliary and colorectal cancers is present in those with inflammatory bowel disease. Although much research involves locating an active therapy that can alter the disease course, the only available treatment is liver transplantation, and risk for disease recurrence remains. Use of ursodeoxycholic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease course. In this Review, we summarise aetiological theories, provide an update on hepatobiliary malignancies that require surveillance, and discuss exciting areas of investigation for potential treatment.

AB - Primary sclerosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associated with inflammatory bowel disease. Although the cause of the disease is still debated, a genetic association and link to immune-mediated disease triggered by environmental factors are thought to contribute. The disease can present as isolated imaging abnormalities, biochemical changes, cholangiocarcinoma, or end-stage complications such as cirrhosis. Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea. Differentiation of primary sclerosing cholangitis can be challenging because other chronic cholangiopathies can present similarly; however, the distinction is necessary to optimise disease surveillance. Management involves assessment for comorbid inflammatory bowel disease and exclusion of other associated cholangiopathic disorders. Patients with primary sclerosing cholangitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepatobiliary and colorectal cancers is present in those with inflammatory bowel disease. Although much research involves locating an active therapy that can alter the disease course, the only available treatment is liver transplantation, and risk for disease recurrence remains. Use of ursodeoxycholic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease course. In this Review, we summarise aetiological theories, provide an update on hepatobiliary malignancies that require surveillance, and discuss exciting areas of investigation for potential treatment.

UR - http://www.scopus.com/inward/record.url?scp=84996497287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996497287&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(16)30010-3

DO - 10.1016/S2468-1253(16)30010-3

M3 - Review article

C2 - 28404115

AN - SCOPUS:84996497287

VL - 1

SP - 68

EP - 77

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 1

ER -